Pharma Focus Asia
KP - Choose our fully recyclable blister films

SK Bioscience Bolsters Strategic Partnership with Novavax through Equity Investment

Wednesday, August 09, 2023

SK Bioscience announced to make an equity investment in Novavax to address endemic challenges.

SK bioscience and Novavax have prolonged their existing licence agreement to include Novavax's newly developed COVID-19 vaccine, designed for annual immunisation. This extended partnership also involves SK bioscience's exploration of future collaborations with Novavax, which will encompass leveraging Novavax's adjuvant, known as 'Matrix-M.'

The extended licence agreement will empower SK bioscience to set up a proactive response system within South Korea's vaccination landscape for the new endemic phase. This agreement is built on a successful partnership that has spanned multiple years, allowing both companies to understand each other's strengths.

As part of the agreement, SK bioscience secures exclusive distribution rights for Novavax's COVID-19 variant vaccine in South Korea, while also gaining non-exclusive distribution rights in Thailand and Vietnam for supply and commercialisation of the vaccine.

The strategic equity investment, combined with the collaboration between SK bioscience and Novavax throughout the pandemic, will create powerful synergy.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024